Clear Search sequence regions


  • Akt (1)
  • atp (2)
  • atp- receptor (2)
  • brilliant blue g (1)
  • cation (1)
  • cellular (2)
  • human (2)
  • kn 04 (1)
  • kn 62 (1)
  • P2X (3)
  • P2X7 (2)
  • P2X7 receptor (1)
  • P2X7R (5)
  • PI3K (1)
  • plasma membrane (1)
  • receptor (5)
  • receptors p2x7 (2)
  • Sizes of these terms reflect their relevance to your search.

    The P2X receptor 7 (P2X7R) is a plasma membrane receptor sensing extracellular ATP associated with a wide variety of cellular functions. It is most commonly expressed on immune cells and is highly upregulated in a number of human cancers where it can play a trophic role in tumorigenesis. Activation of this receptor leads to the formation of a non-selective cation channel, which has been associated with several cellular functions mediated by the PI3K/Akt pathway and protein kinases. Due to its broad range of functions, the receptor represents a potential therapeutic target for a number of cancers. This review describes the range of mechanisms associated with P2X7R activation in cancer settings and highlights the potential of targeted inhibition of P2X7R as a therapy. It also describes in detail a number of key P2X7R antagonists currently in pre-clinical and clinical development, including oxidised ATP, Brilliant Blue G (BBG), KN-62, KN-04, A740003, A438079, GSK1482160, CE-224535, JNJ-54175446, JNJ-55308942, and AZ10606120. Lastly, it summarises the in vivo studies and clinical trials associated with the use and development of these P2X7R antagonists in different disease contexts.

    Citation

    Matthew Drill, Nigel C Jones, Martin Hunn, Terence J O'Brien, Mastura Monif. Antagonism of the ATP-gated P2X7 receptor: a potential therapeutic strategy for cancer. Purinergic signalling. 2021 Jun;17(2):215-227

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 33728582

    View Full Text